Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HINT1 | P49773 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.38 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20149820 | 0.93 | KDM4E (0.58) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL25496203 | 0.92 | KDM4E (0.54) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL26298166 | 0.91 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1HPGDHINT1 | |
| SCHEMBL26298176 | 0.91 | TAS1R3 (0.53) | KDM4ETAS1R3TAS1R1HPGDHINT1 | |
| SCHEMBL20248735 | 0.91 | TAS1R3 (0.57) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL19491652 | 0.91 | TAS1R3 (0.57) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL25496198 | 0.91 | TAS1R3 (0.57) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL25966020 | 0.90 | KDM4E (0.51) | KDM4ETAS1R3TAS1R1ALDH1A1HPGD | |
| SCHEMBL24465153 | 0.89 | TAS1R3 (0.56) | KDM4ETAS1R3TAS1R1HPGDHINT1 | |
| SCHEMBL18510807 | 0.89 | TAS1R3 (0.56) | KDM4ETAS1R3TAS1R1HPGDHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | Janssen Biopharma, Inc. | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | KDM4E 3173/4885TAS1R3 4267/4885TAS1R1 4293/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | KDM4E 3173/4885TAS1R3 4267/4885TAS1R1 4293/4885 |
| US-20230203078-A1 | SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS | NT5C3B, PNP, NME1 | KDM4E 1564/4885TAS1R3 2186/4885TAS1R1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.